The Value of BCG and TNF in Autoimmunity

The Value of BCG and TNF  in Autoimmunity provides an overview of current research and thinking related to tumor necrosis factor (TNF) induction and the use of the bacillus Calmette-Guérin (BCG) vaccine as potential treatment approaches to diverse forms of autoimmunity. BCG, commonly known as an anti-tuberculosis vaccine, is being explored in worldwide clinical trials as an approach to the treatment of certain forms of autoimmunity. The scope of research behind this therapeutic approach spans from the basic science of TNF signaling to research in diverse autoimmune disciplines, such as type 1 diabetes and multiple sclerosis.

Overall, the book focuses on the lessons that can be learned from the researchers' individual experiences and data, and provides a rationale for bringing the inexpensive, generic BCG vaccine to the forefront of clinical trials in different forms of autoimmunity.

Editor awarded 2005: Oprah Achievement Award," Top Health Breakthrough by a Female Scientist"Brings into one resource the international scientific literature on a unique way to treat autoimmunityProvides a different perspective on treatment approaches for certain autoimmune conditionsDiscusses TNF induction, rather than anti-TNF, as a therapeutic pathway for autoimmunity treatment

1. Introduction
2. Mycobacteria, Immunoregulation, and Autoimmunity
3. Prevention of Type 1 Diabetes and Its Recurrence by Immunotherapy with Mycobacterial Adjuvants
4. Proteasome Defects and Cytokine Signaling in Sjögren’s Syndrome
5. The Protective Effect of the BCG Vaccine on the Development of Type 1 Diabetes in Humans
6. Effects of the Bacillus Calmette-Guérin (BCG) Vaccine in the Demyelinating Disease of the Central Nervous System
7. TNF, BCG, and the Proteasome in Autoimmunity: An Overview of the Pathways & Results of a Phase I Study in Type 1 Diabetes
8. Why Test BCG in Sjögren’s Syndrome?
9. Celiac Disease as a Model Disorder for Testing Novel Autoimmune Therapeutics
10. Delivering Solutions and Clinical Benefits for Diseases with Small and Intermediate-Size Patient Populations